Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.
- Author:
Min Kyu KANG
1
;
Dongryul OH
;
Kwan Ho CHO
;
Sung Ho MOON
;
Hong Gyun WU
;
Dae Seog HEO
;
Yong Chan AHN
;
Keunchil PARK
;
Hyo Jung PARK
;
Jun Su PARK
;
Ki Chang KEUM
;
Jihye CHA
;
Jun Won KIM
;
Yeon Sil KIM
;
Jin Hyoung KANG
;
Young Taek OH
;
Ji Yoon KIM
;
Sung Hwan KIM
;
Jin Hee KIM
;
Chang Geol LEE
Author Information
- Publication Type:Original Article
- Keywords: Nasopharyngeal carcinoma; Radiotherapy; Chemotherapy; Chemoradiotherapy
- MeSH: Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Joints; Korea; Multivariate Analysis; Radiotherapy*; Treatment Failure
- From:Cancer Research and Treatment 2015;47(4):871-878
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. MATERIALS AND METHODS: From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy). RESULTS: Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last follow-up, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. CONCLUSION: Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.
